SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

Key Points

• SELLAS Life Sciences Group experienced a significant surge in options trading, with a staggering 761% increase in call options, totaling 59,209 contracts traded on a recent Tuesday.
• Research firm Maxim Group has upgraded its target price for SELLAS Life Sciences from $4.00 to $7.00, rating it as a "buy," while other analysts have given it a consensus rating of "hold."
• The company's stock is currently trading at $1.94, having a market cap of $204.70 million, and has reported earnings history showing a small beat against analysts’ expectations.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of some unusual options trading on Tuesday. Stock investors purchased 59,209 call options on the stock. This represents an increase of 761% compared to the average volume of 6,874 call options.

Analyst Ratings Changes

Several research firms recently weighed in on SLS. Maxim Group increased their target price on SELLAS Life Sciences Group from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $7.00.

SELLAS Life Sciences Group Trading Down 2.8%

NASDAQ SLS traded down $0.06 during mid-day trading on Tuesday, reaching $1.94. 1,555,120 shares of the company's stock traded hands, compared to its average volume of 2,501,245. SELLAS Life Sciences Group has a 1-year low of $0.77 and a 1-year high of $2.27. The company has a fifty day simple moving average of $1.76 and a 200-day simple moving average of $1.66. The company has a market cap of $204.70 million, a price-to-earnings ratio of -5.89 and a beta of 2.62.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Equities research analysts forecast that SELLAS Life Sciences Group will post -0.57 earnings per share for the current fiscal year.

Institutional Trading of SELLAS Life Sciences Group

Several hedge funds have recently made changes to their positions in SLS. Virtu Financial LLC lifted its holdings in shares of SELLAS Life Sciences Group by 30.9% in the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock worth $58,000 after purchasing an additional 12,706 shares during the last quarter. Anson Funds Management LP lifted its holdings in shares of SELLAS Life Sciences Group by 535.7% in the 1st quarter. Anson Funds Management LP now owns 7,579,095 shares of the company's stock worth $8,185,000 after purchasing an additional 6,386,829 shares during the last quarter. Blair William & Co. IL bought a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter worth approximately $35,000. Simon Quick Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter worth approximately $44,000. Finally, ProShare Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter worth approximately $43,000. Institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.